Karim Fizazi and Alicia Morgans discuss various treatment data in the metastatic hormone-sensitive space, including the LATITUDE, CHAARTED and STAMPEDE trials.  The European Consortium Prostate Cancer Consortium in Europe (PEACE) trials were designed for the current generation of prostate and advanced prostate cancer patients and was established in 2013 to facilitate large academic clinical trials for prostate cancer—specifically phase III studies—in Europe. Four PEACE studies are currently planned or ongoing. 

Biographies:

Karim Fizazi, MD, Ph.D. is a medical oncologist, Head of the Department of Cancer Medicine at the Institut Gustave Roussy, Villejuif, France and Professor of Oncology at the University of Paris. He received his medical degree in 1995 and completed a fellowship in 1997, both in medical oncology. He obtained a Ph.D. in Molecular Oncology in 2003.

Alicia Morgans, MD, MPH.

Read More:

A Phase III of ADT + Docetaxel +/- Local RT +/- Abiraterone Acetate in Metastatic Hormone-naïve Prostate Cancer (PEACE I)

A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse (PEACE II)

A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration-Resistant Prostate Cancer Patients Metastatic to Bone (PEACE III)